Elie Saade
Infectious Disease · Cleveland, OHNPI 1164654455
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,543 of the $32,250 with a category attached, or 73.0%. 18 manufacturers reported payments, led by Janssen Research & Development, LLC at 29.7% of the total. Among infectious disease clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $285.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$10K
- Pfizer$8K
- Janssen Global Services, LLC$7K
- Sanofi Pasteur Inc.$5K
- Merck$346
- Gilead$331
- plus $1K from 12 others
Across 49 payments — averaging $8939.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$265K
- Janssen Research & Development, LLC$173K
What the payments were for
- Consulting fees$23,54373%
- Speaking & faculty fees$4,35013%
- Travel & lodging$2,0196%
- Food & beverage$2,1147%
- Education$1971%
- Gifts$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 4 | $9,580 |
| Pfizer | 6 | $8,154 |
| Janssen Global Services, LLC | 4 | $7,495 |
| Sanofi Pasteur Inc. | 3 | $5,026 |
| Merck | 22 | $346 |
| Gilead | 22 | $331 |
| Melinta Therapeutics, LLC | 12 | $267 |
| Insmed, Inc. | 8 | $211 |
| La Jolla Pharmaceutical Company | 2 | $169 |
| Johnson & Johnson | 7 | $158 |
| AbbVie(2 entities) | 6 | $122 |
| Shionogi Inc | 5 | $116 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $104 |
| Janssen Products, LP | 1 | $85 |
| Astellas Pharma US Inc | 2 | $43 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Napo Pharmaceuticals Inc | 1 | $13 |
| Theratechnologies Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zevtera$146
How this compares
$32,250 in reported general payments places this provider in the 90th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Cleveland
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Alan TaegeCleveland$76K
- Benigno RodriguezCleveland$58K
- Robin JumpCleveland$52K
- David CanadayCleveland$24K
- George YendewaCleveland$19K
- Kyle BrizendineCleveland$17K
- Michael LedermanCleveland$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.